Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity.
Acetaminophen (APAP) overdose is a major cause of acute liver failure and serves as a paradigm to elucidate mechanisms, predisposing factors and therapeutic interventions. The roles of apoptosis and inflammation during APAP hepatotoxicity remain controversial. We investigated whether fasting of mice for 24 h can inhibit APAP-induced caspase activation and apoptosis through the depletion of basal ATP. We also investigated in fasted mice the critical role played by inhibition of caspase-dependent cysteine 106 oxidation within high mobility group box-1 protein (HMGB1) released by ATP depletion in dying cells as a mechanism of immune activation. In fed mice treated with APAP, necrosis was the dominant form of hepatocyte death. However, apoptosis was also observed, indicated by K18 cleavage, DNA laddering and procaspase-3 processing. In fasted mice treated with APAP, only necrosis was observed. Inflammatory cell recruitment as a consequence of hepatocyte death was observed only in fasted mice treated with APAP or fed mice cotreated with a caspase inhibitor. Hepatic inflammation was also associated with loss in detection of serum oxidized-HMGB1. A significant role of HMGB1 in the induction of inflammation was confirmed with an HMGB1-neutralizing antibody. The differential response between fasted and fed mice was a consequence of a significant reduction in basal hepatic ATP, which prevented caspase processing, rather than glutathione depletion or altered APAP metabolism. Thus, the inhibition of caspase-driven apoptosis and HMGB1 oxidation by ATP depletion from fasting promotes an inflammatory response during drug-induced hepatotoxicity/liver pathology.
Antoine
Daniel James
DJ
Medical Research Council Centre for Drug Safety Science Department of Pharmacology and Therapeutics, Institute for Translational Medicine, University of Liverpool, Liverpool, UK. d.antoine@liv.ac.uk.
Williams
Dominic P
DP
Kipar
Anja
A
Laverty
Hugh
H
Park
B Kevin
BK
D000082:Acetaminophen / Q000009:adverse effects*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D017209:Apoptosis; D053148:Caspase 3 / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism*; D004032:Diet; D005978:Glutathione / Q000378:metabolism; D024243:HMGB1 Protein / Q000378:metabolism*; D022781:Hepatocytes / Q000473:pathology; D007249:Inflammation / Q000378:metabolism; D008297:Male; D051379:Mice; D009336:Necrosis / Q000473:pathology; D010084:Oxidation-Reduction
D024243:HMGB1 Protein; D000082:Acetaminophen; D000255:Adenosine Triphosphate; D053148:Caspase 3; D005978:Glutathione
Gastroenterology. 2003 Feb;124(2):494-503
12557154
Hepatology. 2006 Feb;43(2 Suppl 1):S31-44
16447272
Biochem Pharmacol. 1995 Jul 17;50(2):155-61
7632158
J Biol Chem. 2004 Feb 27;279(9):7370-7
14660645
Toxicol Appl Pharmacol. 1981 Aug;60(1):66-77
7281177
JAMA. 1994 Dec 21;272(23):1845-50
7990219
J Pharmacol Exp Ther. 1996 Dec;279(3):1470-83
8968373
FASEB J. 2002 Aug;16(10):1227-36
12153990
World J Gastroenterol. 2006 Dec 21;12(47):7666-70
17171797
Toxicol Pathol. 1996 Mar-Apr;24(2):181-9
8992608
J Pharmacol Exp Ther. 2007 Sep;322(3):1208-20
17556636
Carcinogenesis. 1990 May;11(5):847-53
2139818
J Gastroenterol Hepatol. 2007 Jun;22 Suppl 1:S49-52
17567465
Clin Liver Dis. 2007 Aug;11(3):459-75, v
17723915
J Exp Med. 2000 Aug 21;192(4):565-70
10952726
Proc Natl Acad Sci U S A. 1984 Mar;81(5):1327-31
6424115
Science. 1999 Jul 9;285(5425):248-51
10398600
Biochem Biophys Res Commun. 2003 Apr 25;304(1):207-12
12705907
Immunity. 2008 Jul 18;29(1):21-32
18631454
Toxicol Sci. 2009 Dec;112(2):521-31
19783637
Toxicol Pathol. 2010 Feb;38(2):280-6
20097795
Am J Physiol Gastrointest Liver Physiol. 2006 Jun;290(6):G1269-79
16439473
J Exp Med. 1997 Apr 21;185(8):1481-6
9126928
Liver. 1988 Dec;8(6):337-43
3146008
BMJ. 2004 Nov 6;329(7474):1076
15516343
Physiol Genomics. 2004 Apr 13;17(2):230-44
14762175
Am J Physiol. 1994 Jul;267(1 Pt 1):C67-74
8048493
Cancer Res. 1997 May 15;57(10):1835-40
9157970
J Immunol. 2008 Feb 15;180(4):2531-7
18250463
Hepatology. 2006 Jun;43(6):1220-30
16729305
J Pharmacol Exp Ther. 1973 Oct;187(1):185-94
4746326
Toxicol Appl Pharmacol. 2003 Sep 1;191(2):118-29
12946648
Endocrinology. 1998 Mar;139(3):1115-24
9492045
Hepatology. 2002 Jul;36(1):55-64
12085349
Hepatology. 2004 May;39(5):1267-76
15122755
Nat Med. 1996 Jan;2(1):80-6
8564847
J Biol Chem. 1995 Oct 27;270(43):25752-61
7592757
Drug Discov Today. 2007 Apr;12(7-8):336-42
17395094
J Pharmacol Exp Ther. 1973 Oct;187(1):211-7
4746329
Nat Rev Immunol. 2008 Apr;8(4):279-89
18340345
Chem Res Toxicol. 2002 Dec;15(12):1504-13
12482232
Hepatology. 2008 Sep;48(3):889-97
18712839
Gastroenterology. 2007 Jan;132(1):372-83
17241886
Hepatology. 2002 Feb;35(2):289-98
11826401
Nature. 2002 Jul 11;418(6894):191-5
12110890
Hepatology. 2004 Nov;40(5):1170-9
15486922
J Immunol. 2008 Jul 1;181(1):197-207
18566385
Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11942-7
20547845
Life Sci. 2006 Mar 6;78(15):1670-6
16226279
Toxicology. 1992 Nov 1;75(2):97-107
1281344
Gastroenterology. 2004 Dec;127(6):1760-74
15578514